Effect of Tislelizumab Combined with Docetaxel Second-line Treatment on Short-term Efficacy and Tumor Markers in Patients with Advanced Non-small Cell Lung Cancer
CHEN Xi
GUO Jiaxun
GONG Jun
CHEN Jia
SU Xiaoqin
Abstract：Objective:To investigate the effect of Tislelizumab combined with Docetaxel second-line treatment on short-term efficacy and tumor markers in patients with advanced non-small cell lung cancer(NSCLC).Method:A total of 81 patients with advanced NSCLC who admitted to Nantong University Affiliated Cancer Hospital from January 2020 to October 2023 were selected as the research objects,all patients were divided into the observation group(n=40)and the control group(n=41)by odd-even grouping method.The control group was treated with single-agent Docetaxel as the second-line treatment,and the observation group was treated with Tislelizumab combined with Docetaxel second-line treatment,the treatment time was 2 cycles(6 weeks).The short-term efficacy,tumor markers[cytokeratin 19 fragment antigen 21(CYFRA21-1),glycoprotein antigen 125(CA125),carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC)]and inflammatory response[neutrophil/lymphocyte ratio(NLR),platelet/lymphocyte ratio(PLR),systemic immune inflammation index(SII)]before and after treatment,incidence of adverse reactions and prognosis were compared between two groups.Result:The disease control rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05);after treatment,the CYFRA21-1,CA125,CEA,SCC,NLR,PLR and SII in two groups were lower than those before treatment,and those in the observation group were lower than the control group,the differences were statistically significant(P<0.05);there was no significant difference in the incidence of adverse reactions between two groups during treatment(P>0.05);the 1-year survival rate of the observation group was 80.00%(32/40),which was higher than 58.54%(24/41)of the control group,and the difference was statistically significant(P<0.05).Conclusion:Tislelizumab combined with Docetaxel second-line treatment in the treatment of patients with advanced NSCLC is more effective,reducing tumor marker levels and inflammatory factor levels,and improve patient survival rates.
Keywords：Advanced non-small cell lung cancerTislelizumabDocetaxelEfficacyTumor markersInflammatory factors
Publication Date：2025-05-15
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 9-12 )